SENS Senseonics Holdings Inc

$SENS partnership with $BBNX is a great way to further the integration with AID, though granted BBNX is a smaller player than those incumbents.

$SENS last 2 update of Eversense 365 download , we can see that download number is increasing, this is only for the Android market, iOS is not included.

$SENS hmmmm, just for fun i wonder how clowe i’ll be. 9.27 by tomorrow, 9.65 thurs, 10 by friday.

$SENS the common denominator for all incumbent AID players is the poor CGMs currently in use, they are two weeks disposable and much less accurate, much inferior experience comparing with Eversense 365. I think those AID users are crying for reliable, accurate, long term provider of CGM experience. Eversense 365 is filling this huge gap. Will Medtronic, Insulet, Abbot, Tandem pivot to Eversense 365 so that their users can focus more on their lifestyle than technology tinkering?

$SENS bears said don’t but after RS, yet anyone who bought after is up on all shares added since Oct 17 (recent run to 10 excluded). I’ve been consistently adding since, more than doubling my main account from 1000 (20k presplit) to 2400 shares. By no means am I a big investor but as time passes i only become more bullish as my thesis continues to play out until i reassess end of 2027. i cautioned against buying like 2 weeks ago as the price action wasnt looking particularly strong, when to add is important. All that said, I’m fairly confident that moving forward anything under 9 is an extremely safe buy and will be acting accordingly. Important to note, my main account had an avg of just over 6$ so everything from here for me is averaging up. I’ll post my TA read probably early next week to see how OPEx plays out first but things are looking good with this recent backtest.

$SENS FWIW & FYI: I just listened to part of the Senate hearings for the potential confirmation of Heidi Overton, MD, PhD (& Surgeon) as the new FDA Commissioner. Dr. Overton stated she has "Adult Onset Type One Diabetes". If confirmed the Diabetic community will now have someone who is a T1D that obviously understands the challenges that all Diabetics face. Hopefully she will expedite approvals of new meds and products such as the now available E365 - then Gemini & Freedom - and related AID pump systems to assist in everyday living for this community. Best wishes for her health & confirmation. GLTA Longs...

$SENS Senseonics is accelerating into a pivotal new phase of growth. With Eversense 365, the world’s first & only one-year continuous glucose monitoring system, now approved and launched across Europe, Senseonics has expanded its commercial presence beyond the United States into Germany, Italy, Spain, and Sweden, while bringing its European sales and marketing operations in-house. The company delivered record Q2 2026 performance, generating $14.5 million in revenue, up approximately 120% year over year, with gross margin reaching approximately 59% & full-year revenue guidance raised to $62–66 million. U.S. revenue surged more than 150%, quarterly shipments reached an all-time high, active prescribers grew approximately 130%, & Eon Care surpassed 90 nurses. With broader European rollout, tender opportunities, automated insulin-delivery compatibility, and the Gemini and Freedom programs ahead, Senseonics is building momentum toward a more connected, global future in diabetes care.

$SENS Still up over 70% on the three month, she needed a little breather and these bad market days are perfect to do it. I would ignore Barclays. They appear to have a short position that they need to get out of. Next earnings report is coming, and they know 3 time's a trend! If it hits, they'll lose their azzes on those positions.

$SENS Just picked up 462 more shares. Holding 9564 shares, so close to 10k. They will raise full year guidance yet again this upcoming ER. Eversense 365 is most likely selling like hotcakes in the EU. The Germans are well known for precision manufacturing, and Eversense 365 is ahead of competition by miles with its accuracy.

$SENS So based on f.. Barclays coverage, all the progress and revenue grow has zero effect on SP positively with their price target of 10$. Its completely a bs coverage. Smells like coverage for their shorting plan.

$SENS Dexcom MC is $33B if we got to just 10% of that the sare price would be $60+... They have some work to do to get there but it is, at minimum, a feasible goal.

$SENS i was gonna do a TA post next week sometime but its pretty straight forward. recent price action since tapping 10 was a backtest for short term MAs, falling below a large number of them including the 10 DMA back on sept 8. today we are officially above all moving averages with the exception of 200 WMA currently at 11.05. that’s presplit .55. I really don’t see what stops this from squeezing if we break and hold above that.

$SENS I have $2900 USD ready to pull the trigger to buy more if shorts try anything funny. I think Tandem-Senseonics partnership news is next!

$SENS Bought 1 share to track price. This is screaming BUY but we are bearish above $6.33 because we want cheap shares. Pump integration is here, please dip below $6...

$SENS Nope it's already going back up and my funds aren't ready yet 😢. You've been pretty wrong lately, so it might be time to admit that soon.

$SENS 2nd day this week, head fake, show green in pre-market with a big jump; sucks people in via social media, then pull the rug.

$SENS That wasn't exactly the close that I was hoping for, but it's green. Green is good!

$SENS holding calls for 12.5 in January and they are looking scrumptious. Will prolly sell when we get to 11.80 📈🔥

$SENS Compelled to respond to the forum. Love challenges. A squeeze would require more than high short interest: a strong catalyst, rapid price appreciation on much heavier volume, and continued higher short interest with tightening borrow availability. Because SENS was heavily shorted around the post-split equivalent of ~$20, many older shorts remain highly profitable despite this rally. Pressure will increase as SENS approaches the mid-to-upper teens, with ~$20–$25 becoming a critical zone where older shorts approach breakeven or losses and newer shorts are already deeply underwater. Just draw a line from 2/25 to today for proof. Shorts are killing it. Shorts are also LTH’s & SENS has a proven track record of their wet dream. A sustained move through the area I mentioned on heavy volume is the only thing that would accelerate covering, We remain at a remote possiblity of a short squeeze & I couldn’t care less. The tech will win, despite E-level governance incompetence.

$SENS 9/4 Low9.62 Close9.63...Telling hedge funds trying to keep the price down, but now we’ve had 3 straight days where the low/close stayed above $9.62. 90% chance $11 is coming. Shorties already out on 9/4, 9/5, etc.